We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Port Erin | LSE:PEBI | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 4.00 | 5.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMPEBI
RNS Number : 7927M
Port Erin Biopharma Investments Ltd
25 January 2016
25 January 2016
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 31 December 2015
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2015 was 10.79 pence per share, including un-invested cash of GBP24,011. The portfolio is valued under IFRS at bid price.
Net Assets stand at GBP2.5 million including Investments of GBP2.49 million. This quarter's NAV represents an increase of 7.47% from the previous valuation of 10.04 pence per share, which included un-invested cash of GBP67,542. No additional management fee is due to Shellbay Investments Limited.
The reported NAV to 31 December 2015 gained due to strong performance across the portfolio during the quarter. The company's three principal investments continue to show significant growth prospects for 2016 and beyond".
Hot Features
Premium
Unaudited to 31 December 2015 GBP
Fixed Assets
Investments 2,494,733
Current Assets
Sundry Debtors 6,342
Uninvested cash 24,011
Current Liabilities
Creditors: amounts due (23,192)
---------------------------------
2,501,894
Capital and Reserves
Share Capital 23
Share Premium 1,890,142
Reserves 611,729
---------------------------------
2,501,894
Shares in Issue 23,195,558
Net Asset Value per share 10.79 pence
Portfolio Details
Investments as at 31 Value % of Total Portfolio December 2015 ----------------------------- ------------- -------------------- Magna Biopharma Income Fund GBP1,241,145 49.8% Plethora Solutions Holdings GBP348,746 14.0% Summit Corporation GBP438,378 17.6% Other quoted holdings GBP229,826 9.2% Other unquoted holdings GBP236,638 9.4% Total GBP2,494,733 100.0% ----------------------------- ------------- --------------------
For further information, please contact:
Port Erin Biopharma Beaumont Cornish Limited Peterhouse Capital
Investments Limited Limited
The Company Nomad Broker
Denham Eke Roland Cornish/ James Lucy Williams
(+44) (0) 1624 639396 Biddle (+44) (0) 207
(+44) (0) 207 628 3396 469 0936
This information is provided by RNS
The company news service from the London Stock Exchange
END
NAVFMGZMNZGGVZM
(END) Dow Jones Newswires
January 25, 2016 02:00 ET (07:00 GMT)
1 Year Port Erin Chart |
1 Month Port Erin Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
